This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: Substantial evidence showing an association between type 2 diabetes (T2D) and cerebral atrophy, cognitive impairment, and dementia is accumulating. However, relatively little is known about the subclinical effects of high plasma glucose levels within the normal range. The aim of this study was to investigate the association between plasma glucose levels and hippocampal and amygdalar atrophy in a sample of 266 cognitively healthy individuals free of T2D, aged 60–64 years, taking part in a longitudinal study of aging.
Methods: Fasting plasma glucose was assessed at wave 1. Hippocampal and amygdalar volumes were manually traced on 1.5 T MRI scans collected at wave 1 and at wave 2 4 years later. General linear model analyses were used to assess the relationship between plasma glucose and incident medial temporal lobe atrophy after controlling for a range of sociodemographic and health variables.
Results: Plasma glucose levels were found to be significantly associated with hippocampal and amygdalar atrophy and accounted for 6%–10% in volume change after controlling for age, sex, body mass index, hypertension, alcohol, and smoking.
Conclusions: High plasma glucose levels within the normal range (<6.1 mmol/L) were associated with greater atrophy of structures relevant to aging and neurodegenerative processes, the hippocampus and amygdala. These findings suggest that even in the subclinical range and in the absence of diabetes, monitoring and management of plasma glucose levels could have an impact on cerebral health. If replicated, this finding may contribute to a reevaluation of the concept of normal blood glucose levels and the definition of diabetes.
GLOSSARY
- BMI=
- body mass index;
- CRP=
- C-reactive protein;
- FOV=
- field of view;
- GLM=
- general linear model;
- HPA=
- hypothalamic-pituitary-adrenal;
- ICV=
- intracranial volume;
- IGT=
- impaired glucose tolerance;
- MetS=
- metabolic syndrome;
- ROI=
- region of interest;
- T2D=
- type 2 diabetes;
- TE=
- echo time;
- TR=
- repetition time
Footnotes
Study funding: Supported by NHMRC of Australia grants 973302, 179805, and 157125 and by an Australian Rotary Health Research Fund grant. Nicolas Cherbuin and Kaarin Anstey are funded by NHMRC Research Fellowships 471501 and 1002560. This research was partly undertaken at the National Computational Infrastructure facility in Canberra, Australia, which is supported by the Australian Commonwealth Government.
Supplemental data at www.neurology.org
- Received January 18, 2012.
- Accepted April 19, 2012.
- Copyright © 2012 by AAN Enterprises, Inc.
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.